SCHEMBL6402087

SCHEMBL6402087

COc1ccc(NS(=O)(=O)CCN)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.61
CA2 P00918 4/20 0.61
CA12 O43570 3/20 0.53
CA9 Q16790 3/20 0.53
CA4 P22748 2/20 0.53
CA7 P43166 2/20 0.53
GAA P10253 4/20 0.49
MAPK1 P28482 3/20 0.49
LMNA P02545 3/20 0.49
ALDH1A1 P00352 5/20 0.46
MAPT P10636 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
GFER P55789 1/20 0.46
PGR P06401 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
PKM P14618 1/20 0.44
RECQL P46063 2/20 0.44
HPGD P15428 1/20 0.44
KDM4E B2RXH2 1/20 0.44
NPC1 O15118 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3244226 0.86 CA1 (0.65) CA1CA2CA12CA9CA4
SCHEMBL16691162 0.82 CA1 (0.63) CA1CA2GAAMAPK1LMNA
Hydrochloric Acid SCHEMBL30763346 0.80 LMNA (0.51) GAAMAPK1LMNAALDH1A1SMN1; SMN2
Hydrochloric Acid SCHEMBL21633676 0.80 LMNA (0.51) GAAMAPK1LMNAALDH1A1SMN1; SMN2
Hydrochloric Acid SCHEMBL29143512 0.79 CA1 (0.55) CA1CA2CA12CA9CA4
SCHEMBL3755941 0.77 CA1 (0.57) CA1CA2CA12CA9CA4
SCHEMBL23693483 0.76 LMNA (0.47) CA1CA2CA12CA9GAA
SCHEMBL2053820 0.76 PKM (0.58) CA1CA2CA12CA9CA4
SCHEMBL10538487 0.76 CA1 (0.56) CA1CA2CA12CA9CA4
SCHEMBL3763304 0.76 CA1 (0.54) CA1CA2CA12CA9CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900237-B2 Sulfonamide compounds as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2005-05-31 US disclosed
US-20030158231-A1 Sulfonamide compounds as protease inhibitors Celera Corporation 2003-08-21 US disclosed
WO-2003024923-A1 SULFONAMIDE COMPOUNDS AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2003-03-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158231-A1 Sulfonamide compounds as protease inhibitors PRSS1, PRSS3, SPINT2 CA1 228/4885CA2 216/4885CA12 383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.